Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARD | Q03181 | 14/20 | 0.36 |
| ▸ | PPARA | Q07869 | 8/20 | 0.36 |
| ▸ | PPARG | P37231 | 7/20 | 0.36 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.34 |
| ▸ | STK17B | O94768 | 1/20 | 0.33 |
| ▸ | AGXT | P21549 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | CRHBP | P24387 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.33 |
| ▸ | GSTP1 | P09211 | 1/20 | 0.32 |
| ▸ | SCN8A | Q9UQD0 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5862812 | 0.82 | FFAR1 (0.44) | PPARDPPARAPPARGMRGPRX4 | |
| SCHEMBL5860748 | 0.81 | PPARD (0.43) | PPARDPPARAPPARGMRGPRX4 | |
| SCHEMBL5860751 | 0.79 | FFAR1 (0.47) | PPARDPPARAPPARGMRGPRX4AGXT | |
| SCHEMBL6162923 | 0.78 | PPARD (0.62) | PPARDPPARAPPARGMEN1MAPT | |
| SCHEMBL5860969 | 0.77 | STK17B (0.40) | PPARDPPARASTK17BAGXTKDM4E | |
| SCHEMBL2245501 | 0.76 | CCR1 (0.40) | PPARDPPARAPPARGSTK17BAGXT | |
| SCHEMBL5861865 | 0.75 | PPARD (0.50) | PPARDPPARAPPARG | |
| SCHEMBL5861942 | 0.74 | KMT2A (0.37) | PPARDPPARAPPARGKDM4EMEN1 | |
| SCHEMBL5861932 | 0.74 | FFAR1 (0.54) | PPARDPPARAPPARGMRGPRX4 | |
| SCHEMBL5860721 | 0.71 | STK17B (0.39) | STK17BKDM4EMEN1HSP90AA1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7091237-B2 | Furan and thiophene derivatives that activate human peroxisome proliferator activated receptors | SMITHKLINE BEECHAM CORPORATION (US) | 2006-08-15 | — | — | US | disclosed |
| EP-1392674-B1 | FURAN AND THIOPHENE DERIVATIVES THAT ACTIVATE HUMAN PEROXISOME PROLIFERATOR ACTIVATED RECEPTORS | SMITHKLINE BEECHAM CORP (US) | 2005-08-10 | — | — | EP | disclosed |
| US-20040157890-A1 | Furan and thiophene derivatives that activate human peroxisome profilerator activated receptors | GLAXO GROUP LIMITED (GB) | 2004-08-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040157890-A1 | Furan and thiophene derivatives that activate human peroxisome profilerator activated receptors | PPARG, PPARD, PPARA | PPARD 2/4885PPARA 3/4885PPARG 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.